See more : BP p.l.c. (BP-B.L) Income Statement Analysis – Financial Results
Complete financial analysis of Veru Inc. (VERU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Veru Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sabina Public Company Limited (SABINA-R.BK) Income Statement Analysis – Financial Results
- Forum Engineering Inc. (7088.T) Income Statement Analysis – Financial Results
- Destination Maternity Corporation (DESTQ) Income Statement Analysis – Financial Results
- Carlsberg A/S (CABJF) Income Statement Analysis – Financial Results
- KBC Global Limited (KBCGLOBAL.BO) Income Statement Analysis – Financial Results
Veru Inc. (VERU)
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.89M | 16.30M | 39.35M | 61.26M | 42.59M | 31.80M | 15.86M | 13.66M | 22.13M | 32.60M | 24.49M | 31.46M | 35.03M | 18.57M | 22.22M | 27.54M | 25.63M | 19.32M | 14.82M | 11.16M | 8.83M | 9.05M | 8.42M | 6.72M | 5.77M | 4.72M | 5.45M | 2.92M | 2.06M | 2.20M | 16.20M | 12.50M | 11.20M | 13.10M | 10.70M |
| Cost of Revenue | 11.03M | 8.73M | 8.76M | 13.33M | 11.81M | 10.15M | 7.08M | 6.64M | 8.78M | 13.63M | 11.37M | 13.95M | 14.41M | 8.70M | 9.30M | 14.03M | 14.90M | 12.16M | 9.33M | 6.37M | 5.21M | 5.46M | 4.86M | 5.34M | 3.60M | 3.31M | 5.27M | 3.48M | 3.68M | 2.50M | 7.50M | 6.90M | 6.10M | 7.20M | 6.10M |
| Gross Profit | 5.85M | 7.57M | 30.59M | 47.93M | 30.79M | 21.66M | 8.78M | 7.02M | 13.35M | 18.97M | 13.12M | 17.50M | 20.62M | 9.87M | 12.92M | 13.52M | 10.73M | 7.16M | 5.49M | 4.79M | 3.62M | 3.59M | 3.56M | 1.38M | 2.16M | 1.40M | 178.03K | -559.30K | -1.62M | -300.00K | 8.70M | 5.60M | 5.10M | 5.90M | 4.60M |
| Gross Profit Ratio | 34.67% | 46.43% | 77.73% | 78.24% | 72.28% | 68.10% | 55.36% | 51.40% | 60.33% | 58.18% | 53.58% | 55.65% | 58.86% | 53.14% | 58.16% | 49.08% | 41.86% | 37.04% | 37.03% | 42.93% | 41.03% | 39.67% | 42.31% | 20.52% | 37.49% | 29.70% | 3.27% | -19.18% | -78.50% | -13.64% | 53.70% | 44.80% | 45.54% | 45.04% | 42.99% |
| Research & Development | 12.81M | 51.20M | 70.65M | 32.69M | 16.94M | 13.74M | 10.85M | 3.50M | 99.39K | 219.82K | 5.58K | 4.75K | 5.28K | 10.93K | 381.00 | 105.92K | 284.22K | 208.61K | 210.88K | 273.78K | 179.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 361.09K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.02M | 8.66M | 12.13M | 9.14M | 7.49M | 9.63M | 6.23M | 6.43M | 7.01M | 7.04M | 5.89M | 4.82M | 5.71M | 4.46M | 4.89M | 4.93M | 1.85M | 2.97M | 3.14M | 2.90M | 3.04M | 2.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.27K | 88.87K | 0.00 | 58.12K | 221.72K | 52.95K | 332.76K | 220.18K | 191.15K | 223.80K | 179.87K | 218.50K | 123.10K | 47.60K | 36.53K | 43.83K | 129.16K | 0.00 | 0.00 | 433.82K | 1.64M | 2.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.18M | 48.06M | 43.17M | 20.67M | 14.50M | 14.35M | 14.82M | 11.07M | 8.75M | 12.13M | 9.20M | 7.71M | 9.68M | 6.56M | 6.65M | 7.20M | 7.26M | 6.07M | 5.04M | 5.83M | 4.51M | 4.92M | 4.97M | 1.98M | 2.97M | 3.14M | 3.33M | 4.68M | 5.97M | 8.00M | 10.70M | 8.10M | 6.20M | 7.10M | 3.70M |
| Other Expenses | -1.22M | 2.09M | -316.06K | -8.71M | 14.10M | -5.89M | -2.20M | 15.51M | 9.20M | 9.20M | 9.20M | 7.71M | 2.01M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.26M | 0.00 | 1.83M | 1.28M | 0.00 | 0.00 | 0.00 | 100.00K | 500.00K | 400.00K | 300.00K | 200.00K | 100.00K |
| Operating Expenses | 42.77M | 101.35M | 113.81M | 53.36M | 45.53M | 28.09M | 29.65M | 14.58M | 10.33M | 12.35M | 9.20M | 7.71M | 9.68M | 6.57M | 6.65M | 7.30M | 7.55M | 6.28M | 5.25M | 6.10M | 4.69M | 4.92M | 6.23M | 1.98M | 4.80M | 4.43M | 3.33M | 4.68M | 6.33M | 8.10M | 11.20M | 8.50M | 6.50M | 7.30M | 3.80M |
| Cost & Expenses | 53.80M | 110.08M | 122.58M | 66.70M | 57.34M | 38.24M | 36.74M | 21.21M | 19.11M | 25.99M | 20.57M | 21.67M | 24.09M | 15.27M | 15.94M | 21.33M | 22.45M | 18.44M | 14.58M | 12.47M | 9.90M | 10.38M | 11.09M | 7.32M | 8.41M | 7.74M | 8.60M | 8.15M | 10.01M | 10.60M | 18.70M | 15.40M | 12.60M | 14.50M | 9.90M |
| Interest Income | 0.00 | 0.00 | 4.37M | 4.89M | 4.62M | 4.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.17K | 55.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 607.47K | 2.43M | 4.37M | 4.85M | 4.62M | 4.71M | 2.95M | 2.04M | 3.32M | 0.00 | 50.57K | 0.00 | 296.18K | 124.63K | 3.98M | 2.39M | 0.00 | 74.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 268.18K | 269.87K | 209.60K | 593.87K | 783.64K | 471.42K | 452.05K | 481.01K | 422.87K | 494.26K | 589.34K | 556.30K | 461.45K | 464.91K | 466.54K | 268.38K | 217.09K | 252.94K | 333.63K | 522.80K | 1.09M | 1.55M | 1.01M | 923.92K | 1.83M | 1.28M | 533.99K | 553.30K | 675.08K | -100.00K | -500.00K | -400.00K | -300.00K | -200.00K | -100.00K |
| EBITDA | -36.20M | -89.98M | -79.23M | 9.75M | -14.65M | -7.14M | -19.67M | -8.12M | 4.92M | 7.11M | 4.51M | 10.35M | 11.40M | 3.76M | 4.69M | 5.32M | 3.40M | 1.01M | 573.99K | -1.11M | 19.17K | 210.53K | -1.66M | 321.06K | -812.89K | -1.74M | -2.73M | -4.76M | -7.10M | -8.30M | -2.20M | -2.50M | -1.10M | -1.60M | 800.00K |
| EBITDA Ratio | -214.38% | -552.10% | -211.47% | -38.93% | -34.62% | -20.24% | -131.57% | -44.52% | 16.22% | 21.64% | 18.77% | 33.21% | 31.65% | 18.08% | 39.04% | 26.99% | 9.08% | 6.19% | 3.96% | -6.94% | 0.94% | 2.33% | -4.75% | 2.98% | -16.61% | -39.07% | -50.15% | -163.37% | -340.18% | -377.27% | -13.58% | -20.00% | 8.93% | -12.21% | 7.48% |
| Operating Income | -36.92M | -93.78M | -83.22M | -5.44M | -14.75M | -6.44M | -20.87M | -8.49M | 3.02M | 6.62M | 3.92M | 9.79M | 10.94M | 3.30M | 4.35M | 4.72M | 3.18M | 875.91K | 240.36K | -1.31M | -1.07M | -1.34M | -2.67M | -602.86K | -2.64M | -3.03M | -3.15M | -5.24M | -7.95M | -8.20M | -1.70M | -2.10M | 1.30M | -1.40M | 900.00K |
| Operating Income Ratio | -218.61% | -575.46% | -211.47% | -8.88% | -34.62% | -20.24% | -131.57% | -62.20% | 13.64% | 20.30% | 16.02% | 31.12% | 31.23% | 17.75% | 19.57% | 17.13% | 12.42% | 4.53% | 1.62% | -11.75% | -12.09% | -14.76% | -31.72% | -8.98% | -45.75% | -64.17% | -57.80% | -179.62% | -385.12% | -372.73% | -10.49% | -16.80% | 11.61% | -10.69% | 8.41% |
| Total Other Income/Expenses | -160.93K | 1.11M | -316.06K | -8.71M | -5.31M | -5.89M | -2.20M | -108.38K | -204.60K | 68.63K | 33.28K | 144.26K | -147.91K | -63.37K | -125.03K | 332.10K | 1.02M | -7.00K | -12.35K | -44.40K | 0.00 | 0.00 | -1.26M | -568.40K | 145.20K | 100.18K | 117.14K | 79.53K | -252.61K | 0.00 | 1.00M | 0.00 | 600.00K | 400.00K | 200.00K |
| Income Before Tax | -37.08M | -92.67M | -83.54M | 4.27M | -20.05M | -12.32M | -23.07M | -8.60M | 2.81M | 6.69M | 3.96M | 9.93M | 10.79M | 3.23M | 4.22M | 5.05M | 4.20M | 868.91K | 228.01K | -1.33M | -1.07M | 0.00 | -3.93M | -1.17M | -2.49M | -2.93M | -3.03M | -5.16M | -8.20M | 0.00 | -1.50M | 0.00 | -800.00K | -1.00M | 1.00M |
| Income Before Tax Ratio | -219.56% | -568.65% | -212.28% | 6.96% | -47.08% | -38.74% | -145.43% | -63.00% | 12.72% | 20.51% | 16.16% | 31.58% | 30.80% | 17.41% | 19.01% | 18.34% | 16.40% | 4.50% | 1.54% | -11.87% | -12.09% | 0.00% | -46.67% | -17.44% | -43.23% | -62.05% | -55.65% | -176.89% | -397.36% | 0.00% | -9.26% | 0.00% | -7.14% | -7.63% | 9.35% |
| Income Tax Expense | 725.10K | 480.21K | 236.40K | -3.13M | -1.08M | -303.93K | 866.10K | -1.99M | 2.47M | 2.34M | 1.52M | -4.41M | -4.51M | -2.17M | -2.51M | -1.49M | -762.86K | -825.00K | -29.32K | 58.51K | 1.02M | 1.04M | 2.07M | 447.43K | 906.65K | 624.13K | 89.28K | 291.21K | 963.00K | 100.00K | 1.30M | 1.60M | 5.60M | 100.00K | 600.00K |
| Net Income | -37.80M | -93.15M | -83.78M | 7.39M | -18.97M | -12.02M | -23.94M | -6.61M | 344.73K | 4.35M | 2.43M | 14.34M | 15.30M | 5.40M | 6.74M | 6.54M | 4.97M | 1.69M | 282.03K | -1.36M | -2.02M | -2.37M | -3.48M | -1.17M | -3.69M | -3.75M | -3.36M | -5.61M | -8.66M | -8.30M | -3.00M | -3.70M | -4.30M | -1.50M | 300.00K |
| Net Income Ratio | -223.86% | -571.60% | -212.88% | 12.07% | -44.55% | -37.79% | -150.89% | -48.42% | 1.56% | 13.33% | 9.93% | 45.59% | 43.67% | 29.08% | 30.32% | 23.73% | 19.38% | 8.77% | 1.90% | -12.15% | -22.87% | -26.20% | -41.36% | -17.44% | -63.99% | -79.53% | -61.59% | -192.33% | -419.54% | -377.27% | -18.52% | -29.60% | -38.39% | -11.45% | 2.80% |
| EPS | -0.28 | -1.10 | -1.05 | 0.10 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.09 | 0.51 | 0.55 | 0.20 | 0.25 | 0.25 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| EPS Diluted | -0.28 | -1.10 | -1.05 | 0.09 | -0.28 | -0.19 | -0.44 | -0.19 | 0.01 | 0.15 | 0.08 | 0.50 | 0.53 | 0.19 | 0.24 | 0.24 | 0.18 | 0.06 | 0.01 | -0.06 | -0.10 | -0.12 | -0.21 | -0.08 | -0.29 | -0.34 | -0.34 | -0.66 | -1.30 | -1.39 | -0.62 | -0.96 | -1.24 | -0.45 | 0.14 |
| Weighted Avg Shares Out | 134.88M | 84.97M | 80.12M | 76.27M | 66.75M | 63.32M | 53.86M | 34.41M | 28.67M | 28.53M | 28.52M | 28.38M | 27.69M | 27.29M | 26.98M | 25.65M | 26.12M | 24.95M | 23.80M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
| Weighted Avg Shares Out (Dil) | 134.88M | 84.97M | 80.12M | 83.80M | 66.75M | 63.32M | 53.86M | 34.64M | 28.93M | 28.92M | 28.87M | 28.73M | 28.93M | 28.97M | 28.55M | 27.81M | 27.98M | 26.40M | 26.49M | 21.67M | 19.33M | 19.02M | 16.24M | 14.63M | 12.76M | 10.89M | 10.00M | 8.51M | 6.64M | 5.97M | 4.84M | 3.85M | 3.47M | 3.33M | 3.28M |
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-related diseases, today announced that...
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced it will host a conference call and audio webcast...
Advanced Penny Stocks Research Methods
Can these top tips help your penny stocks trading? The post Advanced Penny Stocks Research Methods appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is VERU Stock Up 3% Today?
Veru (NASDAQ: VERU ) stock is getting a boost on Friday after the company revealed plans to sell its ENTADFI capsule business. That sale has the company agreeing to sell the business for $20 million to Blue Water Vaccines (NASDAQ:...
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced the sale of its ENTADFI® (finasteride and tadalafil) capsules...
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases that has a commercial sexual health division, today announced it has...
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Investigational New Drug (IND) meeting with FDA to...
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model
Top 5 Defensive Stocks That Are Set To Fly
The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell Steiner, M.D., Chairman, President and Chief...
Source: https://incomestatements.info
Category: Stock Reports